[HTML] jci.org

[HTML][HTML] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang… - The Journal of …, 2005 - Am Soc Clin Investig
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox …
被引用次数：1245 相关文章

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri… - Journal of Clinical …, 2005 - search.proquest.com
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB (389) IL-2 (also known as denileukin …
[PDF] academia.edu

[PDF][PDF] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang, D Coleman… - academia.edu
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox …

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang… - Journal of Clinical …, 2005 - experts.umn.edu
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB 389 IL-2 (also known as denileukin diftitox …

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang… - The Journal of …, 2005 - pubmed.ncbi.nlm.nih.gov
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB (389) IL-2 (also known as denileukin …

[引用][C] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J DANNULL - J. Clin. Invest., 2005 - cir.nii.ac.jp
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of
regulatory T cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
[HTML] nih.gov

[HTML][HTML] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang… - Journal of Clinical …, 2005 - ncbi.nlm.nih.gov
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB 389 IL-2 (also known as denileukin diftitox …
[PDF] researchgate.net

[PDF][PDF] Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull, Z Su, D Rizzieri, BK Yang, D Coleman… - researchgate.net
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB389IL-2 (also known as denileukin diftitox …

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

J Dannull, Z Su, D Rizzieri, BK Yang… - The Journal of …, 2005 - nsuworks.nova.edu
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB (389) IL-2 (also known as denileukin …

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

J Dannull, Z Su, D Rizzieri, BK Yang… - The Journal of …, 2005 - europepmc.org
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the
recombinant IL-2 diphtheria toxin conjugate DAB 389 IL-2 (also known as denileukin diftitox …